ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

Iniparib Plus Chemo Shows Benefit In Phase II Study

January 28, 2011

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

Page 2: The Debate Over Brigham’s Containment Bag Study

November 21, 2014

NIH scientists defend industry ties while officials vow conflicts review; three investigations planned.

January 23, 2004

Health Organizations: Cancer Center, Organization Join to Promote Awareness Of Skin Cancer

April 11, 1997

NCI To Pay 34 Percent Of Grants, At 155 Payline; $100 Million for Centers to Fund All Core Grants

January 29, 1988